Five Prime Therapeutics — Corporate Update (November 2017)
14 slides from Five Prime Therapeutics's corporate update, Nov 8, 2017
Slide 1: Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO
Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO® and Early Efficacy Signal in Pancreatic Cancer November 8, 2017 Exhibit 99.2
Slide 2: Forward-Looking Statements Disclaimer
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are
Slide 3: Key Takeaways Regarding Cabiralizumab/Opdivo Combination in Pancreatic Cancer
Durable clinical benefit in 5 of 31 patients in pancreatic cancer Including 3 independently confirmed responses in heavily pre-treated patients without microsatellite-instability (MSI) Responses associated with significant reduction in tumor marker CA19-9 Historically, pancreatic cancer without MSI
Slide 4: Pancreatic Cancer in 2017
4th most common cause of death due to cancer in the US (n ≈ 43,090) Higher than breast cancer (40,600) or prostate cancer (26,700)1 Most patients with pancreatic cancer are diagnosed at an advanced stage All stages have poor prognosis; even the earliest stage < 1/3 alive at 5 years In advanced stage
Slide 5: No reported durable monotherapy responses in pancreatic cancer without MSI
There are no reported durable monotherapy responses in pancreatic cancer without MSI: Anti-PD-1 Anti-CTLA4 Anti-PD1 monotherapy is ineffective in pancreatic cancer except in the <1-2% of patients who have microsatellite instability-high (MSI)2 Onivyde® (liposomal irinotecan) is the most recently FDA
Slide 6: Rationale for Targeting CSF1-R-Dependent TAMs in Pancreatic Cancer
Human pancreatic cancer cells and surrounding stroma induce CSF1R-dependent macrophages to a pro-tumor phenotype (Tumor Associated Macrophages) Tumor Associated Macrophages (TAMs) Promote a fibrotic tumor microenvironment, cancer cell survival and migration, and cancer cell resistance to chemotherap
Slide 7: TAM Infiltration is Associated with Poor Prognosis in Pancreatic Cancer
TAM Infiltration is Associated with Poor Prognosis in Pancreatic Cancer © 2017 Five Prime Therapeutics, Inc. All Rights Reserved Kurahara et al., J Surgical Res 2011 Zhu et al., Cancer Research 2014 Pancreatic cancer with a high number of TAMs (identified by CSF1R-dependent gene signature; CD68, MRC
Slide 8: CSF-1R Blockade Acts Synergistically with Anti-PD-1 and Chemotherapy
CSF-1R Blockade Acts Synergistically with Anti-PD-1 and Chemotherapy by Reprograming the Tumor Microenvironment Five Prime Data ORTHOTOPIC PANCREATIC CANCER MODEL + gemcitabine IgG Anti-PD1 Combo p=0.0001 p=0.03 0.0 0.5 1.0 1.5 2.0 Tumor Weight (mean g± SEM) Anti-CSF1R (FPA008) Anti-CSF1R (FPA008) ©
Slide 9: Rationale for Combination Therapy: TAMs and Checkpoints Inhibit T Cell-Mediated Killing
CD8 T Cell Tumor Cell PD-1 PD-L1 TAM CSF-1R PD-L1/PD-1 suppresses T cells TAMs produce factors that inhibit T cells © 2017 Five Prime Therapeutics, Inc. All Rights Reserved Rationale for Combination Therapy: TAMs and Checkpoints Inhibit T Cell-Mediated Killing Through Different Mechanisms
Slide 10: Cabiralizumab/OPDIVO Combination Trial in Multiple Tumor Settings
Cabiralizumab/OPDIVO® Combination Trial in Multiple Tumor Settings © 2017 Five Prime Therapeutics, Inc. All Rights Reserved PHASE 1b Cabiralizumab + OPDIVO ® Study Objectives Cabiralizumab Monotherapy N ~280 patients Safety Objective response rate and duration Survival Baseline and on-treatment biop
Slide 11: Cabiralizumab +/- Nivolumab Demonstrates a Tolerable Safety Profile
Cabiralizumab +/- Nivolumab Demonstrates a Tolerable Safety Profile © 2017 Five Prime Therapeutics, Inc. All Rights Reserved *Includes pneumonitis, respiratory distress and acute respiratory distress
Slide 12: Deep and Durable Responses Observed with Significant Reduction in CA19-9
Deep and Durable Responses Observed Accompanied by Significant Reduction in Pancreatic Tumor Marker CA19-9 © 2017 Five Prime Therapeutics, Inc. All Rights Reserved
Slide 13: Conclusions
Durable clinical benefit in 5 of 31 patients in pancreatic cancer Including 3 independently confirmed responses in heavily pre-treated patients without microsatellite-instability (MSI) Responses associated with significant reduction in tumor marker CA19-9 Historically, pancreatic cancer without MSI
Slide 14: Thank You
NASDAQ:FPRX Thank You www.fiveprime.com
Five Prime Therapeutics — Corporate Update (November 2017) on 6ix